
|Articles|June 20, 2019
June 2019 Digital Edition
Advertisement
Pipeline watch: we look closely at drugs in phase 2, phase 3 or recently approved for basal cell carcinoma and melanoma. Plus, treating patients with autism, and the physician's impact on regulations and pay.
Subscribe to Dermatology Times!
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Skin Cycling
2
First HA Injectable for Neck Wrinkles Cleared by FDA
3
Clinique's Daily Calm Merges Clinical Efficacy with Color Cosmetics for Sensitive Skin
4
Oral STAT6 Degrader KT-621 Delivers Biologics-Like Efficacy in Moderate to Severe AD
5














